[go: up one dir, main page]

MA29730B1 - Detection d'un antigene cible independamment de la presence ou de l'absence d'un anticorps therapeutique correspondant - Google Patents

Detection d'un antigene cible independamment de la presence ou de l'absence d'un anticorps therapeutique correspondant

Info

Publication number
MA29730B1
MA29730B1 MA30617A MA30617A MA29730B1 MA 29730 B1 MA29730 B1 MA 29730B1 MA 30617 A MA30617 A MA 30617A MA 30617 A MA30617 A MA 30617A MA 29730 B1 MA29730 B1 MA 29730B1
Authority
MA
Morocco
Prior art keywords
target antigen
therapeutic antibody
absence
detection
therapeutic
Prior art date
Application number
MA30617A
Other languages
English (en)
Inventor
Helmut Lenz
Werner Scheuer
Martina Thier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA29730B1 publication Critical patent/MA29730B1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE LES ANTICORPS THÉRAPEUTIQUES. L'INVENTION CONCERNE EN PARTICULIER UNE MÉTHODE DE DÉTECTION DE L'ANTIGÈNE CIBLE D'UN ANTICORPS THÉRAPEUTIQUE DANS UN ÉCHANTILLON, CONSISTANT A) À OBTENIR L'ÉCHANTILLON À ANALYSER, B) À INCUBER LEDIT ÉCHANTILLON AVEC L'ANTICORPS THÉRAPEUTIQUE DANS DES CONDITIONS ADAPTÉES POUR LA LIAISON DE L'ANTICORPS THÉRAPEUTIQUE À L'ANTIGÈNE CIBLE, UN COMPLEXE ANTIGÈNE CIBLE-ANTICORPS THÉRAPEUTIQUE ÉTANT AINSI FORMÉ, ET C) À DÉTECTER LE COMPLEXE FORMÉ AU COURS DE L'ÉTAPE (B).
MA30617A 2005-07-06 2008-02-01 Detection d'un antigene cible independamment de la presence ou de l'absence d'un anticorps therapeutique correspondant MA29730B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05014618 2005-07-06
EP06004447 2006-03-06

Publications (1)

Publication Number Publication Date
MA29730B1 true MA29730B1 (fr) 2008-09-01

Family

ID=36922121

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30617A MA29730B1 (fr) 2005-07-06 2008-02-01 Detection d'un antigene cible independamment de la presence ou de l'absence d'un anticorps therapeutique correspondant

Country Status (19)

Country Link
US (1) US20070009976A1 (fr)
EP (2) EP2194380A3 (fr)
JP (1) JP2008545145A (fr)
KR (1) KR20080016939A (fr)
AR (1) AR053948A1 (fr)
AU (1) AU2006265275A1 (fr)
BR (1) BRPI0612591A2 (fr)
CA (1) CA2613187A1 (fr)
CR (1) CR9635A (fr)
EC (1) ECSP088081A (fr)
IL (1) IL188317A0 (fr)
MA (1) MA29730B1 (fr)
MX (1) MX2008000277A (fr)
MY (1) MY157955A (fr)
NO (1) NO20076662L (fr)
NZ (1) NZ564471A (fr)
RU (1) RU2008103608A (fr)
TW (1) TWI312864B (fr)
WO (1) WO2007003420A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1282443B1 (fr) 2000-05-19 2009-09-02 Genentech, Inc. Analyse de detection genique permettant d'ameliorer la probabilite d'une reponse efficace a une therapie du cancer basee sur un antagoniste d'erbb
KR20180091967A (ko) 2004-07-22 2018-08-16 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JP4752031B2 (ja) 2004-10-01 2011-08-17 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 撮像の装置と方法
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1850874B1 (fr) 2005-02-23 2013-10-16 Genentech, Inc. Extension de la periode menant à la progression de la maladie ou à la survie chez les patients atteints du cancer de l'ovaire par le pertuzumab
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US8358354B2 (en) 2009-01-26 2013-01-22 The Board Of Trustees Of The Leland Stanford Junior University Correction of optical abberations
US8248515B2 (en) 2006-02-07 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Variable imaging arrangements and methods therefor
EP2132573B1 (fr) 2007-03-02 2014-04-23 Genentech, Inc. Elément de prévision de la réponse à un inhibiteur de her
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
ES3023516T3 (en) 2011-10-14 2025-06-02 Hoffmann La Roche Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
KR101327542B1 (ko) * 2012-03-15 2013-11-08 광주과학기술원 양자점 기반의 경쟁 면역분석법 및 다중 유세포 분석법을 이용한 시료 중 오염물질의 검출 방법
AU2012232949B2 (en) * 2012-09-28 2014-07-03 Willowtree Holdings Pty Ltd Temporary bulkhead
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
RU2725093C2 (ru) 2014-04-25 2020-06-29 Дженентек, Инк. Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
JP6822980B2 (ja) 2015-05-30 2021-01-27 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性転移性乳癌の治療方法
WO2017087280A1 (fr) 2015-11-16 2017-05-26 Genentech, Inc. Procédés de traitement d'un cancer positif her2
MX2019007801A (es) 2016-12-28 2019-10-30 Genentech Inc Tratamiento de cáncer avanzado con expresión de her2.
ES2835376T3 (es) 2017-01-17 2021-06-22 Genentech Inc Formulaciones de anticuerpos frente a HER2 subcutáneas
CN114984206A (zh) 2017-03-02 2022-09-02 基因泰克公司 Her2阳性乳腺癌的辅助治疗
KR20190140952A (ko) 2017-04-24 2019-12-20 제넨테크, 인크. 막관통 및 인접막 도메인에서의 erbb2/her2 돌연변이
KR20230030621A (ko) 2020-06-29 2023-03-06 제넨테크, 인크. 퍼투주맙 + 트라스투주맙 고정 용량 조합

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1993021319A1 (fr) 1992-04-08 1993-10-28 Cetus Oncology Corporation ANTICORPS HUMANISES SPECIFIES PAR C-erbB-2
CN100415772C (zh) 1996-10-18 2008-09-03 基因技术股份有限公司 抗ErbB2抗体
US7718387B2 (en) * 2001-09-20 2010-05-18 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
ES2392525T3 (es) * 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4

Also Published As

Publication number Publication date
NO20076662L (no) 2008-04-03
BRPI0612591A2 (pt) 2010-11-23
KR20080016939A (ko) 2008-02-22
JP2008545145A (ja) 2008-12-11
EP2194380A2 (fr) 2010-06-09
MY157955A (en) 2016-08-30
WO2007003420A1 (fr) 2007-01-11
MX2008000277A (es) 2008-03-24
EP1902315A1 (fr) 2008-03-26
EP2194380A3 (fr) 2010-07-14
AR053948A1 (es) 2007-05-23
NZ564471A (en) 2010-04-30
CR9635A (es) 2008-02-20
RU2008103608A (ru) 2009-08-20
IL188317A0 (en) 2008-04-13
TW200741203A (en) 2007-11-01
TWI312864B (en) 2009-08-01
AU2006265275A1 (en) 2007-01-11
ECSP088081A (es) 2008-02-20
CA2613187A1 (fr) 2007-01-11
US20070009976A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
MA29730B1 (fr) Detection d'un antigene cible independamment de la presence ou de l'absence d'un anticorps therapeutique correspondant
FR2917174B1 (fr) Analyse multiple d'echantillons sanguins
MX2009009448A (es) Sensibilidad mejorada de determinacion de perfil de anticuerpos a traves de una colocacion en capas incrementada de anticuerpo reportero.
EP1381864A4 (fr) Detection du candida
DE60219207D1 (de) Diagnostisches testverfahren
ATE425266T1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
ATE289685T1 (de) Verfahren zum nachweis von karzinomen in solubilisierten zervikalen körperproben
WO2005041893A3 (fr) Detection des biomarqueurs de l'infarctus aigu du myocarde
WO2007035576A3 (fr) Systeme de biocapteur a resonance plasmonique de surface pour la detection d'antigenes et procede destine a determiner la presence d'antigenes
TW200720441A (en) New labelling strategies for the sensitive detection of analytes
DK2038430T3 (da) Toll-Like-Receptor-4-dysfunktion og de biologiske anvendelser deraf
DE60013320D1 (de) Analytassay-vorrichtung mit vorabsorbieren-zone
DK1384075T3 (da) Fremgangsmåder til detektering af tidlig renal sygdom hos dyr
NO20052161D0 (no) Analysemetode for hjerte-karsykdom
SG164389A1 (en) Detection of a therapeutic antibody in an experimental animal
WO2004084841A3 (fr) Nouveaux anticorps d'albumine anti-feline et procedes de detection de maladies renales precoces
Daniso et al. Development of a point of care (POC) test as an immunobiosensor for okadaic acid detection in mussels
WO2007063326A3 (fr) Dispositif et procede de dosage
WO2006004958A3 (fr) Detection ou mesure d'anticorps par rapport a proteines antigenes dans des tissus ou des echantillons biologiques
ATE413469T1 (de) Rezeptoreinfang-assay
RU2008129048A (ru) Устройство с трансдермальными датчиками аналитов и способы его применения
WO2001027621A3 (fr) DOSAGE IMMUNOENZYMATIQUE D'INHIBITION (iELISA) PERMETTANT DE DETECTER ET QUANTIFIER LES ANTICORPS PRESENTS DANS DES PRELEVEMENTS BIOLOGIQUES
ATE391914T1 (de) Assay
WO2007122512A3 (fr) Séparation de composés conjugués et non conjugués
Caulum et al. Multi-analyte immunoassay using cleavable tags and microchip micellular electrokinetic chromatography